InsiderTrades.com logo
Timothy Rolph net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Timothy Rolph Biography and Net Worth

Co-Founder and Chief Scientific Officer of Akero Therapeutics

Tim Rolph is Co-Founder and Chief Scientific Officer of Akero. Prior to co-founding Akero, Tim led Pfizer’s Cardiovascular & Metabolic Disease Research Unit as Chief Scientific Officer. In his 22 years at Pfizer, Tim led anti-infective research at the company’s Sandwich (UK) laboratories, directing the team that discovered the prototype CCR5 antagonist, maraviroc, launched as a novel antiretroviral for HIV (Celzentry™), before becoming Head of Research in Sandwich and then at Pfizer’s Groton, Conn., laboratories. Under his leadership at Pfizer, Steglatro™ (ertugliflozin) was discovered and developed in partnership with Merck, and launched as a fixed-dose combination with sitagliptin (Steglujan™), a leading oral medication for diabetes. Prior to Pfizer, Tim worked in Glaxo’s veterinary R&D group, initially studying the modulation of growth for food production and then moving into anti-parasitic research for veterinary applications. Tim holds a B.Sc in Biochemistry from the University of London and a D.Phil from the Faculty of Clinical Medicine at the University of Oxford. His pre- and post-doctoral training was at the Nuffield Institute for Medical Research, where he studied the metabolic adaptations of skeletal and cardiac muscle during development.

What is Timothy Rolph's net worth?

The estimated net worth of Timothy Rolph is at least $7.70 million as of March 5th, 2025. Dr. Rolph owns 170,237 shares of Akero Therapeutics stock worth more than $7,701,522 as of March 26th. This net worth evaluation does not reflect any other assets that Dr. Rolph may own. Additionally, Dr. Rolph receives an annual salary of $722,320.00 as Co-Founder and Chief Scientific Officer at Akero Therapeutics. Learn More about Timothy Rolph's net worth.

How old is Timothy Rolph?

Dr. Rolph is currently 70 years old. There are 7 older executives and no younger executives at Akero Therapeutics. Learn More on Timothy Rolph's age.

What is Timothy Rolph's salary?

As the Co-Founder and Chief Scientific Officer of Akero Therapeutics, Inc., Dr. Rolph earns $722,320.00 per year. The highest earning executive at Akero Therapeutics is Dr. Andrew Cheng M.D., Ph.D., President, CEO & Director, who commands a salary of $1,040,000.00 per year. Learn More on Timothy Rolph's salary.

How do I contact Timothy Rolph?

The corporate mailing address for Dr. Rolph and other Akero Therapeutics executives is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. Akero Therapeutics can also be reached via phone at (650) 487-6488 and via email at akero@sternir.com. Learn More on Timothy Rolph's contact information.

Has Timothy Rolph been buying or selling shares of Akero Therapeutics?

During the last quarter, Timothy Rolph has sold $3,359,000.00 in Akero Therapeutics stock. Most recently, Timothy Rolph sold 12,500 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $44.53, for a transaction totalling $556,625.00. Following the completion of the sale, the insider now directly owns 170,237 shares of the company's stock, valued at $7,580,653.61. Learn More on Timothy Rolph's trading history.

Who are Akero Therapeutics' active insiders?

Akero Therapeutics' insider roster includes Kevin Bitterman (Director), Andrew Cheng (CEO), Tomas Heyman (Director), Patrick Lamy (SVP of Commercial Strategy ), Timothy Rolph (Co-Founder and Chief Scientific Officer), William White (CFO), Catriona Yale (Insider), and Jonathan Young (COO). Learn More on Akero Therapeutics' active insiders.

Are insiders buying or selling shares of Akero Therapeutics?

During the last twelve months, Akero Therapeutics insiders bought shares 1 times. They purchased a total of 200,000 shares worth more than $9,600,000.00. During the last twelve months, insiders at the sold shares 58 times. They sold a total of 969,114 shares worth more than $33,269,224.75. The most recent insider tranaction occured on March, 17th when insider Catriona Yale sold 10,000 shares worth more than $447,600.00. Insiders at Akero Therapeutics own 7.9% of the company. Learn More about insider trades at Akero Therapeutics.

Information on this page was last updated on 3/17/2025.

Timothy Rolph Insider Trading History at Akero Therapeutics

See Full Table

Timothy Rolph Buying and Selling Activity at Akero Therapeutics

This chart shows Timothy Rolph's buying and selling at Akero Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$3.36MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$4M-$2M$0$2M$4MTotal Insider BuyingTotal Insider Selling

Akero Therapeutics Company Overview

Akero Therapeutics logo
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $42.68
Low: $41.84
High: $45.18

50 Day Range

MA: $44.85
Low: $22.31
High: $57.56

2 Week Range

Now: $42.68
Low: $17.86
High: $58.40

Volume

276,023 shs

Average Volume

805,773 shs

Market Capitalization

$3.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A